title: Development of GPIIb/IIIa antagonists as antithrombotic drugs.
abstract: Thrombosis represents a major target for development of drugs to prevent and treat a variety of cardiovascular and cerebrovascular diseases, which are the leading cause of morbidity and mortality in the Western world. This review by Andy Nichols and colleagues focuses on a central process in thrombosis, namely platelet aggregation, and how it can be inhibited by antagonists of the adhesion molecule GPIIb/IIIa. Successful and future therapeutic applications of GPIIb/IIIa antagonists, and their pharmacology, are considered in detail.
authors.affiliation: Smith-Kline Beecham Pharmaceuticals, King of Prussia, PA 19406.
authors.forename: A J
authors.initials: AJ
authors.lastname: Nichols
authors.forename: R R
authors.initials: RR
authors.lastname: Ruffolo
authors.forename: W F
authors.initials: WF
authors.lastname: Huffman
authors.forename: G
authors.initials: G
authors.lastname: Poste
authors.forename: J
authors.initials: J
authors.lastname: Samanen
mesh_terms: D000595:Amino Acid Sequence; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000494:pharmacology / Q000502:physiology; D010974:Platelet Aggregation / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors*
chemical_list: D005343:Fibrinolytic Agents; D009842:Oligopeptides; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; C047981:arginyl-glycyl-aspartic acid